COVID-19: Avigan, precautions: Toyama University / Professor Emeritus Shiraki
COVID-19: Avigan
Toyama University / Professor Emeritus Shiraki (Vice President of Senri Kinran University) has co-developed Avigan.
Chinese paper report:
If you prescribe Avigan by the sixth day of onset,
Early disappearance of the virus,
Reducing coughing,
The progression and severity of pneumonia are prevented,
Mortality should drop sharply.
He says that even if treatment is started when the viral load is past its peak, no significant effect can be expected.
Professor Shiraki:
He says at the outpatient clinic, “You should check chest CT for pneumonia and use Avigan to stop it (to stop the progression of pneumonia).”
Early use of Avigan:
Not only does it reduce mortality,
Young patients may experience pulmonary fibrosis (sponge-like failure) due to interstitial pneumonia,
It also makes sense not to leave sequelae such as scarring (scarring due to inflammation)
He added, “Avigans are also useful for the elderly to prevent their sudden deterioration.”
Big challenges:
“Prudent administration for teratogenically affected generations” is needed.
According to Shiraki, the benefits can be expected from early stages (asymptomatic or mild symptoms).
On the other hand, “generations susceptible to teratogenicity must explain and obtain consent in advance.”
“When administered to men, it shifts to semen.”
(Toyo Keizai Online)
https://headlines.yahoo.co.jp/article?a=20200408-00342917-toyo-bus_all&p=4